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ABSTRACT
First line treatment for pancreatic cancer consists of surgical resection, if 
possible, and a subsequent course of chemotherapy using the nucleoside analogue 
gemcitabine. In some patients, an active transport mechanism allows gemcitabine to 
enter efficiently into the tumor cells, resulting in a significant clinical benefit. However, 
in most patients, low expression of gemcitabine transporters limits the efficacy of 
the drug to marginal levels, and patients need frequent administration of the drug 
at high doses, significantly increasing systemic drug toxicity. In this article we focus 
on a novel targeted delivery approach for gemcitabine consisting of conjugating the 
drug with an EphA2 targeting agent. We show that the EphA2 receptor is highly 
expressed in pancreatic cancers, and accordingly, the drug-conjugate is more effective 
than gemcitabine alone in targeting pancreatic tumors. Our preliminary observations 
suggest that this approach may provide a general benefit to pancreatic cancer patients 
and offers a comprehensive strategy for enhancing delivery of diverse therapeutic 
agents to a wide range of cancers overexpressing EphA2, thereby potentially reducing 
toxicity while enhancing therapeutic efficacy.
INTRODUCTION
Pancreatic cancer is an extremely aggressive and 
deadly disease, with a 5-year survival rate of less than 
5%. Most tumors are either locally advanced or have 
metastasized at the time of diagnosis and, intrinsically, this 
cancer is extremely resistant to chemotherapy and radiation. 
Currently, first line treatment for pancreatic cancer consists 
of surgical resection, if possible, and a subsequent course of 
chemotherapy [1]. This chemotherapy usually consists of 
treatment with Gemcitabine [2]. 
In 1997, Burris, et al. published a clinical study 
comparing Gemcitabine to 5-Fluoruracil (5-FU) for the 
treatment of pancreatic cancer [3]. In this study, 126 
patients were enrolled with 63 per treatment group. 23.8% 
of patients showed clinical benefit with Gemcitabine, 
as compared to only 4.8% of 5-FU-treated patients. The 
median survival was 5.65 months for Gemcitabine and 
4.41 months for 5-FU. Finally, 18% of patients treated 
with Gemcitabine were alive at a 12-month time point, 
while survival at this time point for patients treated with 
5-FU was only 2% [3]. This trial encouraged the FDA to 
approve Gemcitabine for the treatment of pancreatic cancer 
in 1998. Gemcitabine is currently a standard treatment 
used for patients with pancreatic cancer, although the drug 
only provides minimal benefit to patients. Gemcitabine 
triphosphate acts as an analog for deoxycytidine 
triphosphate, which allows it to be incorporated into DNA 
during replication. After Gemcitabine is incorporated, 
another nucleotide may be added to the chain, but inhibition 
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of chain elongation subsequently occurs. DNA damage 
repair is not able to remove the drug and, consequently, 
apoptosis occurs [4].
Gemcitabine enters the cell through multiple cell 
membrane transporters, although the sodium-independent 
transporter, hENT1, has been shown to preferentially 
transport Gemcitabine [4]. Though there are multiple 
mechanisms of Gemcitabine resistance, one important 
mechanism revolves around expression of this protein. 
Giovannetti et al. showed that patients with tumors that 
express high amounts of hENT1 have a greater survival 
advantage with Gemcitabine treatment as compared to those 
with lower hENT1 expression [5]. Patients with higher 
hENT1 expression have tumors that can more readily take 
up Gemcitabine, leading to an increased clinical benefit. 
However, in many tumors, low expression of Gemcitabine 
transporters translates into a need for the drug to be 
administered frequently and at high doses, significantly 
increasing systemic drug toxicity.
Because systemic toxicity and drug delivery are 
major issues with most chemotherapeutic agents, the 
creation of targeted therapies that lower the risk of toxicity 
has become an attractive strategy in developing novel 
cancer therapeutics. Targeted therapies focus on attacking 
cancer cells specifically while sparing normal cells to 
reduce side effects. One specific strategy of targeted therapy 
involves modifying currently used drugs to make them 
cancer specific. This often involves identifying a biomarker 
on cancer cells that the modified drug can target. One such 
target is the EphA2 receptor.
Eph receptors are a family of tyrosine kinase 
receptors involved in neuronal connectivity, blood vessel 
development, and cell-cell interactions [6−27]. The receptor 
sub-type EphA2 was identified in cancer cells where it is 
often highly expressed, mediating communication not only 
between individual cancer cells, but also between cancer 
cells and surrounding stromal or vascular cells [6−27]. 
Despite EphA2 overexpression, expression of ephrinA1, 
its ligand, often remains normal even in a cancerous state. 
This can lead to the accumulation of un-activated EphA2 
and subsequent oncogenic activity [6]. 
Peptides have been developed that, similar to the 
natural ligand for this receptor, selectively bind EphA2 
and cause receptor activation and internalization. Hence, 
in principle, these peptides can be chemically linked to 
commonly used chemotherapeutic drugs and act as specific 
delivery agents for these drugs to tumor cells. Once the 
receptor is activated, the peptide and its attached drug are 
internalized via a lysosomal pathway, where the peptide is 
degraded and the drug is released and free to exert its toxic 
effects on the cell [28]. Our previous studies have shown 
that Paclitaxel conjugated with these peptides showed 
increased efficacy in prostate and renal cancers [28−31]. 
EphA2-targeting molecules reported thus far include two 
12-mer peptides, named YSA (of amino acid sequence 
YSAYPDSVPMMS) and SWL (of amino acid sequence 
SWLAYPGAVSYR), that have been identified via phage 
display techniques [32]. Subsequently, we reported on the 
agent YNH (of amino acid sequence YSAYPDSVP(Nle)
(Hsr)S, where Nle and Hsr represent L-norleucine and 
L-homo-serine, respectively) [28, 31] and very recently 
we designed a related EphA2 agonist, named 123B9, that 
presented increased plasma and in vivo stability over YSA 
and YNH [33]. These agents were designed to specifically 
bind to the EphA2 receptor ligand binding domain (LBD). 
We demonstrated that drug conjugates via such agents 
induce receptor activation and internalization of the drug 
selectively to EphA2 expressing cancer cells and tumor 
vasculature [28−31]. In particular, we demonstrated that a 
targeted delivery strategy of Paclitaxel using these EphA2 
targeting agents is more efficacious than Paclitaxel alone 
in xenograft models of pancreatic cancer [30]. 
Gemcitabine, as mentioned above, although the 
current first-line treatment for pancreatic cancer, does not 
offer great therapeutic benefit to most patients. Hence, the 
goal of this study was to design and characterize a novel 
targeted delivery strategy for Gemcitabine by conjugating 
it with our EphA2 targeting agents. Our experiments 
clearly suggest that conjugation of Gemcitabine with our 
EphA2 targeting agents increase its efficacy in animal 
models. Further studies on the use of EphA2 targeting 
agents such as YNH or 123B9 to direct chemotherapy 
to pancreatic cancers is therefore warranted to devise 
innovative and perhaps more effective therapies for this 
invariably fatal and aggressive cancer. 
RESULTS
Design and synthesis of EphA2-targeting agents 
conjugated with gemcitabine
The synthesis of YNH-L2-Gem (YDH-L2-Gem) 
and 123B9-L2-Gem followed the general scheme shown 
in Figure 1. The final drug conjugates were obtained by 
coupling the corresponding YNH, YDH or 123B9 motifs 
(Supplementary Figure S1) to the synthesized azidohexanoyl 
gemcitabine (Figure 1; Supplementary Figure S4). Briefly, a 
stirred solution of azidohexanoyl-gemcitabine (0.097 mmol) 
containing the corresponding EphA2 targeting motif 
(0.105 mmol) in DMSO-water (4:1, 3.0 mL) was added 
to CuSO4 (1.0 M, 50 µL) and sodium ascorbate (1.0 M, 
50 µL) and continually stirred for another 2 days. The 
product was purified on a reverse phase C-18 column by 
HPLC with a gradient of 10–90% acetonitrile-water to give 
the title compounds as white powder.
To further verify the binding affinity and selectivity 
of the resulting conjugates for the EphA2 ligand binding 
domain (LBD), we expressed and purified EphA2 and 
EphA4 ligand binding domains (EphA2-LBD and 
EphA4-LBD). These proteins were dissolved to a final 
concentration of 100 µM in 50 mM phosphate buffer 
(pH = 6.5), containing 100 mM NaCl. Isothermal Titration 
Calorimetry (ITC) measurements under these experimental 
conditions revealed that YNH-L2-Gem and 123B9-L2-
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Gem bound to EphA2 with Kd values of 3.8 µM and 
2.3 µM, respectively (Figure 1; Supplementary Figure S1). 
In contrast, no appreciable binding was observed for the 
scrambled YDH-motif to the EphA2-LBD or for any of 
the agents for the EphA3-LBD (Figure 1; Supplementary 
Figure S1). These data are consistent with our previous 
studies with unconjugated peptides and related Paclitaxel 
conjugates [28−31]. 
Figure 1: Chemical structures and general synthetic scheme used to obtain the EphA2 targeting agents conjugated 
with gemcitabine. (A) Synthetic scheme. Regents and condition: a TBSCl, imidazole, rt, 12 h; b Diallyl pyrocarbonate, Et3N, THF, rt, 
12 h; c 6-azido-hexanoic acid, EDCI, DMAP, DCM, rt, 6 h; d TBAF, THF, rt, 2 h; e (Ph3P)2PdCl2, Bu3SnH, HOAc, THF, 0°C, 2 h; f YNH 
motif or 123B9 motif (Supplementary Figure S1), CuSO4, sodium ascorbate, DMSO/water, rt, 48 hf) YNH motif or 123B9 motif, CuSO4, 
sodium ascorbate, DMSO/water, rt, 48 h. YDH-L2-Gem has the same composition as YNH-L2-Gem except that it contains a scrambled 
peptide of sequence YDPS(Hsr)A(Nle)YSPSVK and it was synthesized using the same general scheme. Analytical data relative to critical 
intermediates and final compounds are reported as Supplementary Figure S4. Isothermal titration calorimetry data for YNH-L2-GEM 
against (B) EphA2 and (C) EphA3 LBD ligand binding domains are reported. For the binding between EphA2 LBD and YNH-L2-GEM the 
data revealed a Kd = 3.8 µM, ∆H = −16 Kcal/mol, −T∆S = −9.1 Kcal/mol. No appreciable binding was detected between YNH-L2-GEM 
and the EphA3 LBD (~50% sequence identity with the EphA2 LBD). Similar data were obtained with 123B9-L2-GEM (Supplementary 
Figure S1). 
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Pancreatic cancer cell lines and human 
pancreatic cancer tissue contain elevated EphA2
Analysis of EphA2 expression in a variety of 
pancreatic cancer cell lines, including MIA PaCa-2, PANC-
1, BxPC-3, and AsPC-1 cells (ATCC) and normal immortal 
LT2 cells (Millipore) was performed using western blotting 
experiments probed with a primary antibody for the 
EphA2 receptor (Cell Signaling, used at 1:1,000 dilution). 
Representative data obtained with 5 × 105 cells are reported 
in Figure 2A. Overexpression of the EphA2 receptor 
appeared evident in all cell lines tested. Among these, the 
MIA-PaCa-2 cell line was chosen for subsequent xenograft 
studies.
Normal human pancreatic tissue, chronic pancreatitis 
tissue, and human pancreatic ductal adenocarcinoma tissue 
[34, 35] were also probed for EphA2 expression using a 
rabbit anti-EphA2 (ab78002, abcam, 1/200). We observed 
that the EphA2 antibody did not appear to stain normal 
tissue (Figure 2B) except perhaps for some slight staining 
around the center of some acini. In chronic pancreatitis 
tissue, we found EphA2 staining in surviving acinar tissue, 
and also in some unknown tissue with characteristic islets 
morphology (Figure 2C). Staining of the EphA2 antibody 
in the human pancreatic adenocarcinoma tissue was evident 
in cancerous, but not in normal ducts and also in some 
fibroblast cells within stroma (Figure 2D). 
EphA2-targeting-gemcitabine conjugates are 
more effective than gemcitabine as single agents 
in xenografts of pancreatic cancer
MIA PaCa-2-luc cells were used to create bilateral 
subcutaneous xenografts in athymic nude mice. Western 
blotting data showed that this pancreatic cancer cell line 
highly expresses EphA2 (Figure 2A). Cells were injected 
into each flank and then allowed to grow for approximately 
1 week. At this point, mice were imaged using BLI and 
treatment was subsequently initiated. Mice were divided 
into 4 groups (PBS, Gemcitabine, YDH-L2-Gemcitabine, 
YNH-L2-Gemcitabine) with 9 mice/group. YDH-L2-
Gemcitabine is a scrambled control, where the peptide 
attached to Gemcitabine should not be specific for EphA2 
and, therefore, should not bind to the receptor. Animals 
were treated 2 times per week via tail vein injection for 
4 weeks. A dose of 10 mg/kg Gemcitabine was used along 
with equimolar doses of YDH-L2-Gemcitabine and YNH-
L2-Gemcitabine. At the end of 4 weeks, animals were again 
imaged and treatment was ended. 
As expected, YDH-L2-Gemcitabine did not have 
significant effects on tumor growth. Gemcitabine had 
a modest effect on tumor growth, though YNH-L2-
Gemcitabine showed the greatest inhibition of tumor growth 
of all groups evaluated (Figure 3A). This can be observed 
both through tumor measurement and by BLI (Figure 3B). 
Figure 2: Expression pattern of EphA2 in cancer cells and pancreatic tissues. (A) Western blotting of normal pancreatic 
fibroblasts (LT2) and pancreatic cancer cells (Panc-1, MIA-PaCa-2, AsPc-1, BxPc-3). Immunostaining of (B) normal pancreatic cancer 
tissue, (C) chronic pancreatitis tissue, and (D) pancreatic ductal adenocarcinoma tissue. EphA2 antibody appears to stain the surviving acinar 
tissue of chronic pancreatitis tissue (panel C), indicated by the orange arrow. In addition, some unknown tissue with islets characteristic 
morphology with high intensity within stroma of CP tissue is stained, as indicated by violet arrows (panel C). In the pancreatic ductal 
adenocarcinoma tissue, the EphA2 antibody stains cancer glands (red arrow, panel D) but not normal appearing tissues and ducts. Fibroblast 
cells also stains slightly. Normal ducts indicated by blue arrow.
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No negative side effects of the drugs were observed and 
the mouse weight remained consistent throughout the 
study. 3 animals per group were sacrificed at the end of this 
study and tumors were excised and fixed in formalin for 
future analyses. The remaining mice were sacrificed only 
when they reached a moribund status. From this study we 
observed that both Gemcitabine and YNH-L2-Gemcitabine 
treated mice displayed a significant increase in the median 
survival time compared to untreated mice (Supplementary 
Figure S2). 
Similarly, in a separate experiment we compared the 
efficacy of equimolar doses of Gemcitabine and 123B9-L2-
Gem (Figure 3C, 3D). As in the case of YNH-L2-Gem, we 
found that 123B9-L2-Gem was significantly more effective 
than gemcitabine alone in suppressing tumor growth. 
However, the median survival time of 123B9-L2-Gem 
treated mice was significantly longer than both untreated 
and Gemcitabine treated groups (Supplementary Figure S2). 
This again suggests that the targeted delivery approach 
may result in an accumulation of the drug in the EphA2 
expressing tumor cells (See also Supplementary Figure S5). 
DISCUSSION
Though not overly efficacious, chemotherapy remains 
the mainstay of pancreatic cancer therapy. There is a 
vital need to develop novel therapies that provide greater 
clinical benefit to patients without undue toxicity. A Phase 3 
clinical study in patients with metastatic pancreatic cancer 
evaluated nab-Paclitaxel (Abraxane) + Gemcitabine versus 
Gemcitabine alone in a total of 861 patients. The median 
survival was 8.5 months in the nab-paclitaxel + Gemcitabine 
group vs. 6.7 months in the Gemcitabine group. The survival 
rate at 1 year was 35% vs. 22%; 9% vs. 4% at 2 years. The 
response rate was 23% for combination group and 7% for 
Gemcitabine alone. Toxicities included neutropenia, fatigue, 
and neuropathy [36]. These results encouraged the FDA to 
approve the combination of Gemcitabine and nab-Paclitaxel 
for metastatic pancreatic cancer.
Accordingly, in preliminary experiments we 
investigated whether the efficacy of Gemcitabine against 
pancreatic cancer as a single agent could be improved using 
our recently developed targeted delivery strategy. First, we 
developed drugs conjugates that are capable of specifically 
targeting the EphA2 receptor, which is overexpressed on 
the surface of pancreatic cancer cells. Initial studies used 
Gemcitabine linked to the YNH peptide and its scrambled 
control YDH-L2-Gem (Figure 1). Similarly, we synthesized 
123B9-L2-Gem, in which the terminal tyrosine of the 
EphA2 targeting peptide, which is essential to specific 
EphA2 binding, was replaced with a bioisoster, resulting in 
increased stability and longer half-life in vivo of the agent 
[30]. Our previous studies demonstrated that YSA-L1-
palitaxel conjugates, when administered in prostate cancer 
Figure 3: In vivo efficacy studies with gemcitabine and its EphA2-targetting-gemcitabne conjugates. Each treated mice 
received the equivalent of 10 mg/Kg of Gemcitabine. (A) YNH-L2-Gemcitabine inhibits tumor growth in vivo to a greater extent as 
compared to Gemcitabine. Tumor volume is reported as calculated by caliper tumor measurement (blue diamonds, control; red squares, 
Gemcitabine; green circles, YNH-L2-GEM; violet triangles, YDH-L2-GEM); for statistical comparisons we used the two-way Anova 
analyses (GraphPad), ****p < 0.0001. (B) Bioluminescent tumor images taken for representative mice in each group at Day 34. Exposure 
time = 0.5 seconds. (C) In vivo efficacy studies with Gemcitabine and its 123B9-L2-Gem conjugate (blue diamonds, control; red squares, 
Gemcitabine; green circles, 123B9-L2-GEM) (D) Bioluminescent tumor images taken for representative mice in each group at day 33. 
Exposure time = 0.5 seconds.
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(PC3) xenografts bearing mice resulted in the accumulation 
of the drug in the tumor, using extraction and LC/MS 
analysis [28]. Here, we chose the L2 linker as we recently 
studied in details the degradation of these conjugates in 
plasma [29] and in vivo [30] and concluded that this linker 
is stable and long lived compared to previously proposed 
linker. In particular, the hydrolysis of the L2 linker and 
concomitant delivery of the free payload started to occur 
after 8 hr incubation of the conjugate with rat plasma 
[29]. To further corroborate these previous findings we 
conjugated 123B9 or a scrambled version with a near 
infrared dye (Supplementary Figure S5) for in vivo imaging 
studies. Similar to what previously found using LC/MS 
analysis [28], we observed increased fluorescence in the 
tumor site in mice bearing PC3 xenografts compared to mice 
that received a scrambled-NIR conjugate (Supplementary 
Figure S5) further supporting that the proposed targeting 
agents can direct the payload at EphA2 rich tumor sites. 
Hence, to investigate whether these findings in prostate 
cancer could be translated to pancreatic cancers, we 
subsequently evaluated the expression of the EphA2 
receptor in a variety of pancreatic cancer cell lines. Most 
cell lines tested exhibited elevated EphA2 levels and among 
these we selected the MIA PaCa-2 cell line for subsequent 
in vivo studies (Figure 2A). In addition, and perhaps of 
most relevance, EphA2 overexpression appeared evident in 
diseased versus normal pancreatic tissues (Figure 2B–2D). 
Hence, we preliminarily evaluated the ability of these 
novel targeting agents to inhibit tumor growth in pancreatic 
cancer xenograft studies using the MIA PaCa-2 cell line. 
Gemcitabine as a single agent at the chosen dose and 
regimen did not exhibit significant efficacy compared to 
mice treated with vehicle only as control, as indicated by 
tumor growth (Figure 3). On the contrary, significant efficacy 
was observed in the xenograft studies in mice receiving 
either YNH-L2-Gem or 123B9-L2-Gem (Figure 3). 
In addition, a significant increase in survival time was 
observed in mice treated with 123B9-L2-Gem compared to 
both Gemcitabine treated and untreated groups. 
Our preliminary studies on the expression patterns 
in pancreatic tissues from human biopsies clearly 
indicated elevated EphA2 in the diseased versus normal 
pancreatic tissue (Figure 2B–2D). The EphA2 antibody 
did n’t appear to stain normal pancreatic tissue, whereas 
staining of surviving acinar tissue and the stroma of 
chronic pancreatitis tissue was evident. In addition, in 
human pancreatic ductal adenocarcinoma, the EphA2 
antibody clearly stained cancerous ducts and fibroblast 
cells within stroma. These data strongly suggest that our 
targeted delivery approach may be even more efficacious 
in the natural micro-environment of the pancreas. In 
conclusion, albeit at preliminary stages, our data support 
the use of these novel EphA2-targeting drug conjugates 
suggesting that they may provide an exciting new strategy 
for pancreatic cancer drug development. Overall, these 
studies provide encouraging evidence that conjugation of 
chemotherapy to our EphA2 targeting agents may have 
potential to improve clinical outcome in pancreatic cancer 
patients. Additional studies on 123B9-L2-Gem and/or 
YNH-L2-Gem as single agents or in combination with 
nab-paclitaxel (Abraxane), perhaps using more complex 
genetically modified models of pancreatic cancers with an 
intact immune system that recapitulate pancreatic cancer 
development in patients, are warranted to further evaluate 
these exciting perspectives. 
MATERIALS AND METHODS
Synthesis and characterization of EphA2 
targeting agents conjugated with gemcitabine
All linear peptides and peptide mimetics were 
assembled using standard Fmoc peptide synthesis protocol 
with the Rink amide resin on 433A Peptide Synthesizer 
(Applied Bio-Systems). In general, in each coupling 
reaction, approximately 10 equivalents of Fmoc-amino acid, 
0.45 M solution of HOBt/HBTU (9 equiv) in DMF, 2 M 
solution of DIEA in NMP were used, for about 9 minutes. 
Fmoc de-protection was performed with 20% piperidine in 
DMF for 10 min. Each peptide was subsequently cleaved 
from the resin and all protecting groups removed by 
exposure to a 94% TFA, 2 % water, 2% tri-isopropylsilane, 
2% phenol mixture for approximately 3 h. The TFA mixture 
was subsequently removed under reduced pressure and the 
peptides were precipitated in diethyl ether, centrifuged, and 
washed with diethyl ether prior to drying in high vacuum. 
The crude peptides were purified by preparative reverse 
phase HPLC. The final compounds were characterized by 
NMR and MALDI-Mass. All compounds were of > 95% 
purity. EphA2-LBD and EphA3-LDB were expressed as 
reported recently [30]. 
Isothermal Titration Calorimetry (ITC) measurements 
were obtained with Model ITC200 from Microcal/GE Life 
Sciences. For in vivo studies, all drugs were diluted in 10% 
Tween-80, 10% DMSO, and 80% PBS. 
EphA2 expression levels in human cell lines and 
tissues
MIA PaCa-2, PANC-1, BxPC-3, and AsPC-1 
cells were all obtained from the American Type Culture 
Collection (ATCC). LT2 immortal normal mesenchymal 
cells were purchased from Millipore. MIA PaCa-2 and 
PANC-1 were maintained in DMEM plus 10% FBS. 
BxPC-3 and AsPC-1 cells were maintained in RPMI plus 
10% FBS. LT2 cells were maintained with media according 
to distributor’s instructions. Cell lines were expanded and 
cryopreserved at early passages and new vials were thawed 
and used for experiments approximately every 3 months. 
5 × 105 cells were plated in 6-cm dishes and treated as 
described. After 48 hours, whole cell lysates were prepared 
and western blotting analysis was carried out as previously 
Oncotarget17109www.impactjournals.com/oncotarget
described [37]. Primary antibodies used for these studies 
were EphA2 (1:1,000, Cell Signaling) and EF1-α (1:5,000, 
Sigma). Representative data are reported in Figure 2A. 
Normal pancreatic tissue (N-pancreas) chronic 
pancreatitis tissue (CP), and Pancreatic ductal 
adenocarcinoma (PDAC) tissue were obtained from an 
IRB approved protocol at Cedar-Sinai Medical Center 
(34086) and probed for EphA2 expression using a rabbit 
anti-EphA2, (ab78002, abcam, 1/200). Representative data 
are reported in Figure 2B–2D. 
Subcutaneous xenograft studies
5 × 106 MIA PaCa-2-luciferase cells were used to 
establish bilateral subcutaneous tumors on the flanks of 
8–10 week old male athymic nude mice. Studies were 
done as previously described [33]. Treatment began when 
tumors reached a palpable size (~50–100 mm3) with 
9 mice per group. All drugs were administered by tail 
vein injection twice per week for 4 weeks, for a total of 
8 injections. Gemcitabine was given at a dose of 10 mg/kg 
and all Gemcitabine derivatives were given at equimolar 
doses to 10 mg/kg Gemcitabine (hence we injected 
~70 mg/Kg of the conjugated having a MW ~7 times 
greater than Gemcitabine), also via tail vein injection. 
BLI measurements were performed at the beginning and 
end of the study. During imaging, mice were placed in 
the imaging chamber and maintained with 2% isoflurane 
gas anesthesia at a flow rate of approximately 0.5–1 
L/min per mouse. Anesthetized mice were injected IP 
with 150 mg/kg body weight D-Luciferin (Xenogen 
Corporation, Alameda, CA). After approximately 10 
min, mice were imaged using a charge-coupled-device 
(CCD) camera coupled to the Xenogen in vivo imaging 
(IVIS) imaging system (Caliper Life Sciences, Inc., 
Hopkinton, MA). 
Tumors were measured twice per week using calipers. 
For in vivo studies, data shown are the mean + SEM 
and for statistical comparisons we used the two-way 
Anova analyses (GraphPad). After their last injection, 
mice were kept for 1 additional week to monitor tumor 
growth and imaged at the end of that week. The mice 
were then kept to monitor for the effects of treatment on 
survival. Mice were kept until reaching a moribund status 
and they were then sacrificed at that time. 
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